Category Archives: Pharmacogenomics

ANALYSIS/OPINION:

I watched my son battle through the darkest depths of depression. My familys struggle to find a treatment that would work was one of the most painful experiences any mother could endure. Depression is a wide-ranging problem that demands bold and innovative solutions. But currently, the Food and Drug Administration is taking action to shut the door when it comes to innovative genetic testing that identifies treatments for depression.

When it comes to mental health Ive learned that the status quo often means a frustrating trial-and-error process of medication selection. Advances in genetics are changing that. Innovative genetic testing is now being used to personalize the treatment of depression and mental illness. This testing helped save my 13-year-old sons life.

When my sons adolescent angst and ADHD intensified over the years into a far more serious struggle with the depths of depression, we pursued a series of treatments. We tried regular therapy and doctors appointments, psychiatry, and what felt like endless trials of a colorful assortment of antidepressants and mood stabilizers.

Nothing seemed to impact on my sons condition and well-being. Still, there was little substantive discussion about taking a fresh approach to his medication regimen. At one point, I begged his physician to consider alternatives. It was then that she suggested a pharmacogenomic test that measures how a persons genetic variations influence their response to different medications.

The test results immediately highlighted alarming issues in my sons treatment regimen and the dosages he was prescribed. Together with his doctor, we made the decision to wean him off several of his medications and begin an alternative protocol that was better suited to his DNA. The test helped guide what drugs and dosages to try.

As a parent who had felt a loss of control, this test gave a newfound sense of control, understanding and hope. The new course of treatment has had a meaningful and enduring impact on my son and the results were evident within months.

Hindsight is always 20/20 but I wonder if some of the trial and error in his treatment was avoidable. Innovations like pharmacogenomic tests should play an important role in improving depression treatment and helping patients like my son get better.

It is therefore deeply concerning that the Food and Drug Administration is taking actions that restrict the use of pharmacogenomic testing. While a level of caution is understandable, it is striking that a regulator would make such a far-reaching move without engaging key stakeholders, including families like mine, who can speak to the life-changing benefits of these tests. Now more than ever, we need advances in technology and personalized medicine to achieve better patient outcomes in depression. We need the government to be part of the solution, not a barrier to progress.

Corey Welsh is a health care industry professional, mental health advocate, and the proud mom of two children. She resides in Chicago, Illinois.

Original post:
Improving treatment for depression in the young - Washington Times

Report Description

A recent market intelligence report that is published by Data Insights Partner ontheglobal Waterproofing Chemicals marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and internationalWaterproofing Chemicals market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and globalWaterproofing Chemicals market overthe short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of globalWaterproofing Chemicals market isoffered. In accordance with the report, theglobal Waterproofing Chemicals market isprojected to expand at a CAGR of10%over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Waterprofing chemicals are the chemical products which are used to protect the internal and external areas for water proofing for several types of materials (most particularly concrete and plastic materials). The key companies available in the market provide those water proofing chemicals as standard chemicals as well as customized on the basis of the requirements of the clients. The advantages for using the water proofing chemicals are excellent durability of the materials, prevention of honeycombing, improved surface finished, less damage by the chemicals present in the water etc. The global Waterproofing Chemicals market is primarily driven by the increasing cost effectiveness of water proofing chemicals, and high quality of constructions in coastal areas in developed nations. Conversely, the growth of the global Waterproofing Chemicals market would likely to restrain by the less adoption rate Waterproofing Chemicals in developing countries in the upcoming period. However, new product development, strategic alliances such as collaborations among key players, marketing activities etc. would provide the global Waterproofing Chemicals market an opportunity to propel during the forecast period. For instance, Berger Paints acquired a Kolkata based firm in October 2019- the Kolkata based firm which is a stalwart in making construction chemicals, also has another division related to waterproofing chemicals. On the other hand, Pidilite Industries India Private Limited, has fortified its marketing campaign to strengthen its Dr. Fixit, waterproofing chemicals division through the celebrity endorsement (or TVC campaign).

Request for Report Sample:https://datainsightspartner.com/request-for-sample?ref=130

Segment Covered:

This market intelligence report on the global Waterproofing Chemicals market encompasses market segments based on technology, application, chemicals, and country. On the basis of application, the global Waterproofing Chemicals market is segregated into floors and basements, waste and water management, tunnel liners, and roofing and walls. In terms of technology, the global Waterproofing Chemicals market is categorized coating and lams, integral systems, and preformed membranes. In terms of chemistry, the global market is classified into bitumen, PVC, TPO, EPDM, elastomars and others. By country/region, the global Waterproofing Chemicals market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as SIKA AG, Fosroc International Limited, The DOW Chemical Company, BASF SE, Pidilite Industries Limited, Drizoro S.A.U., Mapei S.P.A, and others have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Waterproofing Chemicals related investment & spending and developments by major players of the market are tracked in this global report.

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Request for Report Analysis:https://datainsightspartner.com/report/waterproofing-chemicals-market/130

Salient Features:

This study offers comprehensive yet detailed analysis of theWaterproofing Chemicals market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2018 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the worldWaterproofing Chemicals marketis done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overview

Leading market players covered this report comprise names suchSIKA AG, Fosroc International Limited, The DOW Chemical Company, BASF SE, Pidilite Industries Limited, Drizoro S.A.U., Mapei S.P.A, andamong others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market forWaterproofing Chemicals catersto the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors forWaterproofing Chemicals market.The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in theWaterproofing Chemicals market

vIdentification of key factors driving investment opportunities in theWaterproofing Chemicals market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events. Identify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects. Identify key strengths and weaknesses of important market participants

Go here to see the original:
Pharmacogenomic (PGx) Testing Market Projected to Experience Major Revenue Boost during the Period between 2018-2028 - Health News Office

New York, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pharmacogenomics Market by Technology, Application, and End User: Opportunity Analysis and Industry Forecast, 2017 - 2025" - https://www.reportlinker.com/p05793256/?utm_source=GNW

The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61% from 2018 to 2025. Pharmacogenomics is the field of science that evaluates the genetic makeup of an individual that affects the response to drugs. Pharmacogenomics combines the knowledge of pharmacology and genomics. It deals with the interaction of genetic variation and its influence over the drug response in patients by correlating genetic expression and its variability leading to drugs efficacy or toxicity. There has been a surge in demand for the use of pharmacogenomics as a tool to customize and optimize drug therapy to suit the patients genomic profile ensuring maximum efficacy and minimal adverse effects. Pharmacogenomics is a branch which studies the correlation between the genomic profile of the patient and the effects of drug over it. Pharmacogenomics belongs to the field of personalized medicine that promises the development of pharmacogenomics-based diagnostics tests in which drugs and drug combinations are optimized suiting the individual genotype. Pharmacogenomics is a field of science dealing with the identification of single nucleotide polymorphism in the interspecies and the effects it has over the drug diagnosis test that is used to identify the best suited drug, which is expected to not have an adverse effect on the patient and help the drug act effectively on the target. There is an increase in the demand for pharmacogenomics-based drug discovery and diagnostics owing to growth in prevalence of cancer, drug recalls, surge in awareness of pharmacogenomics diagnosis for treatment of cancer, higher number of R&D studies, and rise in adoption of pharmacogenomics in the development of drugs for pain management with better efficacy. Government initiatives and huge investments by private companies in R&D drive the pharmacogenomics market. Furthermore, surge in the aging population and rise in the global incidences of cancer are anticipated to boost the market growth. The application of high throughput genomic technologies in biomedical research and therapeutic procedures accelerate the market progression. The global pharmacogenomics market is segmented based on technology, application, end user, and region. Based on technology, the market is segregated as polymerase chain reaction, microarray, sequencing techniques, mass spectrometry and electrophoresis. Based on application, the pharmacogenomics market is further categorized into cancer, cardiovascular diseases, infectious diseases, neurological diseases and pain management among others. Based on end user, it is segmented as hospitals & clinics, research institutions and academic institutes. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

KEY MARKET BENEFITS The study provides an in-depth analysis of the global pharmacogenomics market share along with the current trends and future estimations to elucidate the imminent investment pockets. The report presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. An extensive analysis of the market based on application assists in understanding the trends in the industry. The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

Market by Technology o Polymerase Chain Reaction o Microarray o Sequencing o Mass Spectrometry o Electrophoresis o Others

Market by Application o Oncology o Infectious diseases o Cardiovascular diseases o Neurological diseases o Psychiatry o Pain management o Others

By End User o Hospitals and clinics o Research institutions o Academic institutes

By Region North America o U.S. o Canada o Mexico Europe o Germany o France o UK o Rest of Europe Asia-Pacific o Japan o China o India o Australia o Rest of Asia-Pacific LAMEA o Brazil o Rest of LAMEA The list of key players operating in this market includes: Abbott Laboratories Admera Health Dynamic DNA Laboratories Empire Genomics, LLC F. Hoffmann-La Roche Ltd. Illumina, Inc OneOme, LLC Myriad Genetics Inc OPKO Health, Inc (GeneDx.) Thermo Fisher Scientific, Inc

The other players included in the value chain analysis (and not included in the report) include: Teva Pharmaceutical Industries Ltd. Assurex Health Inc. Admera Health Bayer AGRead the full report: https://www.reportlinker.com/p05793256/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See original here:
The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61%...

Grand Park Director Named to Board By Reed Parker Writer/Reporter2019-10-24T13:23:49Z

Grand Park Sports Campus Director William Knox has been named to the Advisory Board for Sportology 2020, a nationwide sports technology conference. Knox will discuss how technology can best support the sports industry and events community. The conference is set for March 2020 in Fort Worth, Texas. Knox holds a degree from Indiana University.

A new regional flight option is coming to Indianapolis. United Airlines will Sunday begin offering local customers flights on what it calls the worlds only two-cabin, 50-seat regional aircraft to Chicago OHare.

Zionsville-based 120WaterAudit has added two tech veterans to its executive team. The tech company, which provides a cloud-based water software platform, says the additions will support its continued momentum, following its recently-completed $7 million funding round.

While construction workers in Wisconsin were responsible for laying the keel of the brand new combat ship USS Indianapolis, the duty of commissioning the vessel is bestowed upon Indiana. The states first U.S. Navy vessel commissioning ceremony will take place Saturday at the Port of Indiana-Burns Harbor.

The vast expanse of wind turbines in northwest Indiana appears to be set for expansion. Northern Indiana Public Service Co., a subsidiary of Merrillville-based NiSource (NYSE: NI), and Texas-based EDP Renewables North America LLC have agreed to collaborate on a 302-megawatt wind farm in White County.

Read more:
Manchester University to Add Master's Degree in Nutrition - Inside INdiana Business

Interpace hosts 2nd Annual Fellow Programs

PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid and GI products at an industry known scientific international meeting. The American College of Gastroenterology annual meeting is held on October 27-30 in San Antonio, Texas and is one of the largest gatherings of gastroenterologists and endoscopists. These are two key targets for Interpaces PancraGEN test for early detection of cancer in indeterminate pancreatic cysts, solid lesions, and biliary structures. The PancraGEN publication entitled Serial molecular testing of pancreatic cyst fluid over time: progression and regression highlights the Companys unique clinical and molecular database of patient results, examining 2,167 patients with pancreatic cysts that underwent multiple PancraGEN tests over time. The results support the high negative predictive value of PancraGEN, showing that the majority of cases (92%) initially found to have low risk PancraGEN results remained low risk at follow-up. The small portion of patients that did progress only progressed to moderate risk levels, where risk most often regressed to low risk over time.

In addition to the poster, Interpace will host its second annual Fellows program. The keynote speakers will be Dr. Tamas Gonda, Columbia University, and Dr. James Farrell, Yale University. Dr.s Gonda and Farrell are going to be discussing their peer-reviewed published work on the utility of DNA analysis in managing patients with pancreatic cysts, describing molecular results of patients who have undergone PancraGEN testing and how those results can be used to impact patient management decisions.

About Interpace

Interpace is a leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Interpaces Diagnostic Business is a fully integrated commercial and bioinformatics business unit that provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Interpaces Biopharma Business provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. The Biopharma Business also advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpaces website at http://www.interpacediagnostics.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company's future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company's control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from those expressed or implied by any forward-looking statement. Known and unknown risks, uncertainties and other factors include, but are not limited to the fact that there is no assurance the acquisition of the BioPharma business of Cancer Genetics, Inc. will be successfully integrated with the Company, or that the potential benefits of the acquisition, including future revenues, will be successfully realized. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Company's most recent Annual Report on Form 10-K, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Story continues

Read more from the original source:
Interpace to Present at the American College of Gastroenterology Conference - Yahoo Finance

Why is pharmacogenetics important?

When initiating drug therapy to treat a particular condition, healthcare practitioners typically prescribe one of several appropriate drugs. Dosages and timing of drugs are usually based upon the anticipated rate of metabolism and clearance from the body in the average person. They prescribe a "standard" dose based on factors such as weight, sex, and age. Clinically, however, each person responds uniquely to treatment and healthcare practitioners must make adjustments. For example, the healthcare practitioner may adjust the drug dose or switch to a different therapy, depending on whether the person's condition is responding to the medication and whether the individual is experiencing unpleasant or dangerous side effects. Sometimes a person may find that a treatment that has been working well suddenly causes symptoms when that person starts taking an additional drug.

The concentrations or effects of some drugs are monitored with blood tests and the drug dosages may be increased or decreased to maintain the drug level in an established therapeutic range. Follow-up of drug concentration is called therapeutic drug monitoring. If changing the drug dose is not effective in treating or controlling the person's condition, or the person still has side effects, then the person may be given a different drug.

In contrast, pharmacogenetics offers healthcare providers the opportunity to individualize drug therapy for people based on their genetic make-up. Testing people prior to initiating drug therapy to determine their likely response to different classes of drugs is a key emerging area of testing. Such genetic information could prove useful to both the healthcare practitioner and patient when choosing current and future drug therapies and drug doses. For certain medications, pharmacogenetics is already helping healthcare providers predetermine proper therapies and dosages to have a better chance of achieving the desired therapeutic effect while reducing the likelihood of adverse effects.

Genes are the basic units of genetic material, the segments of DNA that usually code for the production of specific proteins, including the proteins known as enzymes. Each person has two copies of most genes: one copy is inherited from the person's mother and one copy is inherited from the person's father. Each gene is made up of a specific genetic code, which is a sequence of nucleotides (A, T, G, or C). For each nucleotide position in the gene, one of the four nucleotides is the predominant nucleotide in the general population. This nucleotide is usually referred to as "wild type." If an individual has a nucleotide that is different from "wild type" in one copy of his or her genes, that person is said to have a heterozygous variant. If an individual has the same variant nucleotide in both copies of his or her genes, that person is said to have a homozygous variant.

Nucleotide or genetic variants (also called polymorphisms or mutations) occur throughout the population. Some genetic variants are benigndo not produce any known negative effect or may be associated with features like height, hair color, and eye color. Other genetic variants may be known to cause specific diseases. Other variants may be associated with variable response to specific medications.

Pharmacogenetic tests look for genetic variants that are associated with variable response to specific medications. These variants occur in genes that code for drug-metabolizing enzymes, drug targets, or proteins involved in immune response. Pharmacogenetic tests have the ability to determine if a variant is heterozygous or homozygous, which can impact an individual's response or reaction to a drug.

A healthcare practitioner may test a patient's genes for certain variations that are known to be involved in variable response to a medication at any time during treatment (for example, prior to treatment, during initial phase of treatment, or later in the treatment). The results of the testing may be combined with the individual's clinical information, including age, weight, health and other drugs that they are taking, to help tailor therapy. Sometimes, the healthcare practitioner may use this information to adjust the medication dose or sometimes to choose a different drug. Pharmacogenetic testing is intended to give the healthcare practitioner additional information but may not replace the need for therapeutic drug monitoring.

Pharmacogenetic testing for a specific gene is only performed once since a person's genetic makeup does not change over time. Depending on the medication, a single gene may be ordered or multiple genes may be ordered. An example of a medication for which multiple genes are usually evaluated is warfarin, which can be affected by genetic variation in CYP2C9 and VKORC1.

Testing may be ordered prior to starting specific drug therapies or if a person who has started taking a drug is experiencing side effects or having trouble establishing and/or maintaining a stable dose. Sometimes a person may not experience such issues until other medications that affect the metabolism or action of the drug in question are added or discontinued.

Pharmacogenetic testing is available for a relatively limited number of drugs. Some tests may only be applicable to specific ethnic groups. The following are examples of some drugs for which pharmacogenetic tests are available:

Currently they are only indicated if a person is going to take, or is taking, a drug that has an accepted pharmacogenetic test associated with it.

No. The FDA may recommend this testing, as in the case of irinotecan, but it is not required.

Your genetic make-up does not change over time. You may, however, have other pharmacogenetic tests performed if you take a different drug with a different associated pharmacogenetic test.

No. Since there are other factors that affect drug levels besides your genetics, therapeutic drug monitoring may still be necessary.

A blood sample is obtained by inserting a needle into a vein in the arm. Saliva samples and buccal swabs, collected by brushing the inner side of the cheek with a swab, can also be used.

Pharmacogenetic tests are performed to evaluate a person's potential response to a drug therapy. Most genetic tests have been developed to help diagnose or predict the development of a genetic disease, for forensic medicine purposes, and in establishing parentage. Another common use of genetic testing is to detect the genetic material (DNA or RNA) of bacteria and viruses to help diagnose an infection. (Read the article The Universe of Genetic Testing for more information.)

You may be monitored differently depending on the results of the test, especially when starting the medication, changing the dose, or when adding or discontinuing another medication.

This is a question to discuss with your healthcare provider and your family members. In some cases it may be useful; in others it may only be relevant if they are going to be taking the same drug or a drug in the same class. Pharmacogenetic test results are useful information for a family member to share with the healthcare practitioner along with the family's medical history.

You and your healthcare provider should consider the condition that you have, your history of drug-related side effects and/or adverse drug reactions, the drug therapies that are available, and the uses the test is intended for. Pharmacogenetic tests are not meant to stand alone but are meant to be used in conjunction with your other clinical findings.

Pharmacogenetic testing is available for a relatively limited number of medications. Pharmacogenetics tests are generally not widely used and not all insurers will cover their cost. Individuals should consult with their healthcare practitioners about these issues.

Pharmacogenetic tests are intended to provide the healthcare practitioner and patient with additional information when selecting drug treatments and dosages. For a better understanding, patients may want to consult with a genetic counselor prior to and after having a pharmacogenetic test performed. Genetic counseling and informed consent are recommended for all genetic testing.

To learn more about the role of pharmacogenetics in personalized medicine, visit the Personalized Medicine Coalition website.

The rest is here:
Pharmacogenetic Tests | LabCorp